Hey Treed, not odd at all, you are correct as per the Mesoblast power point slide.
And yes Meso bought Osiris in 2013, as to the origins of when/how etc those MSC were developed...it doesn't matter too much because they are now MSB proprietory cells.
Rem L is branded Ryoncil in USA, Temcell in Japan. Treatment cells do not differ when treating aGHVD same as Chronic GHVD, Crohns etc. as per MSB presentation slide. The dosage and tweeks may? The slide is in the the half year presentation on page 16 released 27/2/20.
I would just change the language you used to Mesoblast has given JCR a license to market Mesoblast Stem cells under the brand name Temcell to treat aGHVD.
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-537
-
- There are more pages in this discussion • 311 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.0¢ |
Change
-0.020(2.08%) |
Mkt cap ! $1.073B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | 97.0¢ | 93.5¢ | $1.424M | 1.507M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 29390 | 93.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 14089 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |